BURCON NUTRASCIENCE CORP (BU.CA) Stock Fundamental Analysis
Canada - TSX:BU - CA1208313009 - Common Stock
2.4 CAD
+0.05 (+2.13%)
Taking everything into account, BU scores 2 out of 10 in our fundamental rating. BU was compared to 27 industry peers in the Chemicals industry. BU may be in some trouble as it scores bad on both profitability and health. BU is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
BU had negative earnings in the past year.
In the past year BU has reported a negative cash flow from operations.
BU had negative earnings in each of the past 5 years.
In the past 5 years BU always reported negative operating cash flow.
1.2 Ratios
BU has a Return On Assets of -36.62%. This is in the lower half of the industry: BU underperforms 77.78% of its industry peers.
The Return On Equity of BU (-274.39%) is worse than 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.62% | ||
| ROE | -274.39% | ||
| ROIC | N/A |
ROA(3y)-113.59%
ROA(5y)-75.48%
ROE(3y)-292.02%
ROE(5y)-182.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BU has been increased compared to 1 year ago.
BU has more shares outstanding than it did 5 years ago.
BU has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -7.71, we must say that BU is in the distress zone and has some risk of bankruptcy.
BU's Altman-Z score of -7.71 is on the low side compared to the rest of the industry. BU is outperformed by 74.07% of its industry peers.
BU has a Debt/Equity ratio of 5.27. This is a high value indicating a heavy dependency on external financing.
BU has a Debt to Equity ratio of 5.27. This is in the lower half of the industry: BU underperforms 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.27 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.71 |
ROIC/WACCN/A
WACC6.23%
2.3 Liquidity
BU has a Current Ratio of 1.23. This is a normal value and indicates that BU is financially healthy and should not expect problems in meeting its short term obligations.
BU's Current ratio of 1.23 is in line compared to the rest of the industry. BU outperforms 40.74% of its industry peers.
A Quick Ratio of 1.14 indicates that BU should not have too much problems paying its short term obligations.
BU's Quick ratio of 1.14 is in line compared to the rest of the industry. BU outperforms 51.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.14 |
3. Growth
3.1 Past
The earnings per share for BU have decreased strongly by -1785.82% in the last year.
The Revenue has grown by 16.90% in the past year. This is quite good.
BU shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 66.28% yearly.
EPS 1Y (TTM)-1785.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1868.65%
Revenue 1Y (TTM)16.9%
Revenue growth 3Y30.91%
Revenue growth 5Y66.28%
Sales Q2Q%46.68%
3.2 Future
BU is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 224.01% yearly.
The Revenue is expected to grow by 228.16% on average over the next years. This is a very strong growth
EPS Next Y-803.01%
EPS Next 2Y224.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year153.85%
Revenue Next 2Y228.17%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BU. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 0.36, which indicates a rather cheap valuation of BU.
BU's Price/Forward Earnings ratio is rather cheap when compared to the industry. BU is cheaper than 100.00% of the companies in the same industry.
BU's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 31.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 0.36 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BU's earnings are expected to grow with 224.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y224.01%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BU!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:BU (11/6/2025, 7:00:00 PM)
2.4
+0.05 (+2.13%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners5.92%
Inst Owner ChangeN/A
Ins Owners30.89%
Ins Owner ChangeN/A
Market Cap30.46M
Revenue(TTM)487.00K
Net Income(TTM)-9870600
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.67%
Min Revenue beat(2)-95.36%
Max Revenue beat(2)66.02%
Revenue beat(4)1
Avg Revenue beat(4)-52.8%
Min Revenue beat(4)-95.36%
Max Revenue beat(4)66.02%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-2152.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-69.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 0.36 | ||
| P/S | 62.54 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.47 | ||
| P/tB | 13 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.03
EYN/A
EPS(NY)6.58
Fwd EY274.24%
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0.04
BVpS0.28
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.62% | ||
| ROE | -274.39% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-113.59%
ROA(5y)-75.48%
ROE(3y)-292.02%
ROE(5y)-182.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.27 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 23.61% | ||
| Cap/Sales | 56.82% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | -7.71 |
F-Score2
WACC6.23%
ROIC/WACCN/A
Cap/Depr(3y)68.17%
Cap/Depr(5y)195.49%
Cap/Sales(3y)82.83%
Cap/Sales(5y)124.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1785.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1868.65%
EPS Next Y-803.01%
EPS Next 2Y224.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)16.9%
Revenue growth 3Y30.91%
Revenue growth 5Y66.28%
Sales Q2Q%46.68%
Revenue Next Year153.85%
Revenue Next 2Y228.17%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.58%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.39%
OCF growth 3YN/A
OCF growth 5YN/A
BURCON NUTRASCIENCE CORP / BU.CA FAQ
What is the fundamental rating for BU stock?
ChartMill assigns a fundamental rating of 2 / 10 to BU.CA.
Can you provide the valuation status for BURCON NUTRASCIENCE CORP?
ChartMill assigns a valuation rating of 3 / 10 to BURCON NUTRASCIENCE CORP (BU.CA). This can be considered as Overvalued.
How profitable is BURCON NUTRASCIENCE CORP (BU.CA) stock?
BURCON NUTRASCIENCE CORP (BU.CA) has a profitability rating of 0 / 10.
What is the earnings growth outlook for BURCON NUTRASCIENCE CORP?
The Earnings per Share (EPS) of BURCON NUTRASCIENCE CORP (BU.CA) is expected to decline by -803.01% in the next year.